Merz Pharma invests over 100 million euros in Dessau expansion

Merz Pharma is significantly boosting its presence in Dessau-Roßlau, Germany, with a substantial investment exceeding 100 million euros. This expansion project, set to continue until 2028, will enhance the site's production, packaging, and logistics capabilities.

The investment is driven by a global surge in demand for neurotoxins. Philip Burchard, CEO of the Merz Group, stated the company's confidence in Germany as a long-term industrial hub. "We are convinced that we can produce internationally competitively here in the long term," Burchard explained. "With the expansion, we are responding to the globally increased demand for neurotoxins and consolidating our value creation locally."

This expansion is expected to benefit not only Merz Pharma but also its employees and the broader economic region of Saxony-Anhalt. State Governor Sven Schulze highlighted the positive impact of these investments.

The Merz Group, headquartered in Frankfurt am Main, employs approximately 450 people in Dessau and has a global workforce of 5,500. In the last fiscal year, the group reported a turnover of over 2.2 billion euros. The expansion in Dessau is a strategic move to meet growing market needs while reinforcing the company's commitment to its German operations.